C4ADS has done some extremely impressive work here, especially given how complex ownership and supply chains can be in China. Side Effects is one of the more stunning recent examples of what a group of talented researchers can determine with access to WireScreen. See for yourself: https://lnkd.in/e5PdZcDf
NEW: If you’ve been to your local pharmacy lately, there’s a chance that something you bought was produced with active ingredients that can be traced to #XUAR — and that it was manufactured using #Uyghur #forcedlabor. In Side Effects, we look at the human rights implications of those global pharmaceutical supply chain ties to the region. #China is the largest active pharmaceutical ingredient producer — and the second-largest pharmaceutical market — in the world. And many of the companies responsible for creating and maintaining that market rely on manufacturing bases in XUAR, a hotspot for human rights abuses and a key hub for several of China’s largest pharmaceutical companies (like Sinopharm, Xinjiang Dejuan Bioengineering, and Xinjiang Nuziline Bio-Pharmaceutical). In fact, 76 different pharmaceutical products exported from China are *only* produced in XUAR, including some over-the-counter pain relievers. For global supply chains, this means clear risk of exposure to forced labor. Still, several key global bodies continue to register and source from these XUAR-linked companies — including the FDA and USAID, as well as Japan’s Pharmaceuticals and Medical Devices Agency. As the global community continues to coalesce around forced labor legislation, it’s our hope that policymakers and private-sector actors alike can use the insights found in this report to bolster sanctions, derisk supply chains, and improve due diligence systems. Read ?? https://lnkd.in/e5PdZcDf